Tag: Inventiva
Inventiva: abstract planned at the AASLD conference – 2022-10-24 at 07:43
(CercleFinance.com) – Inventiva announces the selection of a scientific abstract for The Liver Meeting 2022 conference, organized by the AASLD from November 4 to 8 in Washington, which assesses the…
Inventiva announces the presentation of a scientific abstract during The Liver Meeting™ 2022 organized by AASLD – 2022-10-21 at 22:00
Daix (France), Long Island City (New York, United States), October 21, 2021 Daix (France) – Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the date of publication and presentation of its results for the first half of 2022 – 09/07/2022 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the date of publication and presentation of its results for the first half of 2022 – 09/07/2022 at 10:00 p.m.
Daix (France), Long Island City (New York, USA) September 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small…
Inventiva climbs towards 5 euros, an analyst adjusts the target
By Claude Leguilloux Published on 08/11/2022 at 11:21 inventive climbed 2.2% to 4.96 euros on Thursday, while Jefferies is no longer targeting a course…
Analyst recommendations: Crédit Agricole, Ubisoft, Arkema, Sensorion, Poxel, Nanobiotix, Inventiva
Jefferies is very active this Thursday morning, with a review of stocks in the health sector, in particular biotechs. Analyst recommendations: Crédit Agricole, Ubisoft, Arkema, Sensorion, Poxel, Nanobiotix, Inventiva |…
Inventiva publishes its financial information for the first half of 2022 – 2022-07-28 at 22:00
Daix (France), Long Island City (New York, United States), July 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: screening of the first American patient of a trial – 07/08/2022 at 08:50
(CercleFinance.com) – Inventiva announces the screening in the United States of the first patient in its Phase IIa clinical trial LEGEND combining lanifibranor and empagliflozin in patients with NASH (non-alcoholic…
Inventiva: Screening of the first American patient in a trial
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Inventiva raises 14.6 million euros
Biotech is beefing up its cash flow. It has visibility until the end of the second quarter of 2023. The Dijon biotech, at the forefront in the fight against non-alcoholic…
Inventiva strengthens its cash position by almost 15 ME
(Boursier.com) — inventive announces the strengthening of its cash position for an amount of approximately €14.6 million, through its “At-The-Market” (ATM) program for an amount of approximately €9.3 million, and…
Inventiva: encouraging presentations for lanifibranor – 06/10/2022 at 08:22
(AOF) – Inventiva has announced the selection of three scientific abstracts for poster presentation at the International Liver Congress 2022 organized by the Association for the Study of the Liver…